Compare TransMedics Group Inc (TMDX) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Williams Companies Inc — how do they compare? TransMedics Group Inc trades at $77.87 (market cap $2.74B), while Williams Companies Inc trades at $72.67 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 32.3× TransMedics Group Inc's market cap, and Williams Companies Inc pays a 2.9% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Williams Companies Inc for 58 Days on average.
| TMDX | WMB | |
|---|---|---|
Market Cap | $2.74B | $88.48B |
Volume | 949,331 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $150.42 | $79.40 |
52-Week Low | $61.99 | $56.51 |
Typical Hold Time | 24 Days | 58 Days |
Enterprise Value | $3.13B | $119.11B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
WMB trades at $72.34, up 1.23% with strong technical momentum and bullish analyst sentiment. The stock shows solid fundamentals with $11.95B revenue, 25.18% net margin, and consistent dividend growth. Recent earnings beat expectations in Q1 2026, while technical indicators signal bullish momentum with support at $71-72 levels. The company benefits from natural gas demand growth driven by AI data center expansion and maintains stable fee-based revenue streams.
Outlook remains positive with 79% analyst buy ratings and $87.27 consensus target, representing 21% upside. Key opportunities include AI-driven natural gas demand and strategic acquisitions, while risks involve energy market volatility and high debt levels. The stock offers compelling value with strong cash flow generation and dividend growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
